MedTrace Logo

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

NCT01449682 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-05-31

Study results available
· View outcomes & findings →

Summary

To test the efficacy of a 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular function and recalcitrant macular edema associated with retinal vein occlusion following treatment with 2 or more prior intravitreal anti-VEGF drug injections.

Conditions

  • Retinal Vein Occlusion
  • Macular Edema

Interventions

DRUG

Ozurdex

0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies

DRUG

Ozurdex

0.7 mg intravitreal DEX implant on first visit then every 16 weeks

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Retina Macula Institute

    lead OTHER

Principal Investigators

  • Ron P Gallemore, M.D. Ph.D · Retina Macula Institute

  • Behnam Sharareh, B.S · Retina Macula Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-07-31
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01449682 on ClinicalTrials.gov